|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
381,510,000 |
Market
Cap: |
169.20(M) |
Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,808 |
52
Week Range: |
$0.4435 - $1.88 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
500,000 |
525,000 |
525,000 |
Total Buy Value |
$0 |
$324,050 |
$343,050 |
$343,050 |
Total People Bought |
0 |
1 |
2 |
2 |
Total Buy Transactions |
0 |
1 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Klaskin Christine M |
VP Finance |
|
2016-04-26 |
4/A |
D |
$4.15 |
$14,745 |
D/D |
(3,553) |
52,816 |
|
- |
|
Klaskin Christine M |
VP Finance |
|
2016-04-26 |
4/A |
A |
$4.15 |
$43,280 |
D/D |
10,429 |
55,369 |
|
- |
|
Baysal Ozer |
Chief Business Officer |
|
2016-04-26 |
4/A |
D |
$4.15 |
$14,712 |
D/D |
(3,545) |
33,633 |
|
- |
|
Baysal Ozer |
Chief Business Officer |
|
2016-04-26 |
4/A |
A |
$4.15 |
$54,274 |
D/D |
13,078 |
37,178 |
|
- |
|
Ballantyne Charles Evan |
Chief Financial Officer |
|
2016-04-26 |
4 |
D |
$4.15 |
$29,195 |
D/D |
(7,035) |
14,648 |
|
- |
|
Ballantyne Charles Evan |
Chief Financial Officer |
|
2016-04-26 |
4 |
A |
$4.15 |
$89,984 |
D/D |
21,683 |
21,683 |
|
- |
|
Baysal Ozer |
Chief Business Officer |
|
2016-04-26 |
4 |
|
$4.15 |
$14,562 |
D/D |
3,509 |
9,438 |
|
- |
|
Baysal Ozer |
Chief Business Officer |
|
2016-04-26 |
4 |
A |
$4.15 |
$53,730 |
D/D |
12,947 |
12,947 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2016-04-26 |
4 |
D |
$4.15 |
$14,596 |
D/D |
(3,517) |
6,808 |
|
- |
|
Klaskin Christine M |
VP, Finance |
|
2016-04-26 |
4 |
A |
$4.15 |
$42,849 |
D/D |
10,325 |
10,325 |
|
- |
|
Armen Garo H |
Chief Executive Officer |
|
2016-04-26 |
4 |
D |
$4.15 |
$109,755 |
D/D |
(26,447) |
1,296,026 |
|
- |
|
Armen Garo H |
Chief Executive Officer |
|
2016-04-26 |
4 |
A |
$4.15 |
$295,667 |
D/D |
71,245 |
1,322,473 |
|
- |
|
Stein Robert Benjamin |
Chief Scientific Officer |
|
2016-04-26 |
4 |
D |
$4.15 |
$50,900 |
D/D |
(12,265) |
20,776 |
|
- |
|
Stein Robert Benjamin |
Chief Scientific Officer |
|
2016-04-26 |
4 |
A |
$4.15 |
$137,120 |
D/D |
33,041 |
33,041 |
|
- |
|
Valentine Karen |
Chief Legal Officer |
|
2016-04-26 |
4 |
D |
$4.15 |
$33,146 |
D/D |
(7,987) |
16,587 |
|
- |
|
Valentine Karen |
Chief Legal Officer |
|
2016-04-26 |
4 |
A |
$4.15 |
$101,982 |
D/D |
24,574 |
24,574 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2016-03-07 |
4 |
B |
$4.03 |
$805,600 |
D/D |
200,000 |
1,251,228 |
2.74 |
- |
|
Baysal Ozer |
Chief Business Officer |
|
2016-01-04 |
4 |
A |
$4.46 |
$27,875 |
D/D |
6,250 |
21,850 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2015-12-30 |
4 |
D |
$4.63 |
$750,060 |
D/D |
(162,000) |
1,051,228 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2015-12-29 |
4 |
S |
$4.57 |
$389,602 |
D/D |
(85,224) |
1,213,228 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2015-12-28 |
4 |
S |
$4.59 |
$618,276 |
D/D |
(134,352) |
1,298,452 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2015-10-02 |
4 |
D |
$4.82 |
$291,610 |
D/D |
(60,500) |
1,432,804 |
|
- |
|
Armen Garo H |
Chairman & CEO |
|
2015-10-01 |
4 |
A |
$6.61 |
$553,237 |
D/D |
83,697 |
1,493,304 |
|
- |
|
Sharp Shalini |
Director |
|
2015-09-28 |
4 |
A |
$4.59 |
$100,980 |
I/I |
22,000 |
104,270 |
|
- |
|
Ballantyne Charles Evan |
Chief Financial Officer |
|
2015-09-25 |
4 |
B |
$5.05 |
$50,500 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
186 Records found
|
|
Page 7 of 8 |
|
|